SPIA
NPCE icon

Steward Partners Investment Advisory’s Neuropace NPCE Stock Holding History

Steward Partners Investment Advisory’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94K Buy
+300
New +$4.5K ﹤0.01% 3874

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Steward Partners Investment Advisory's NPCE Position: Q1 2026 in Review

Steward Partners Investment Advisory opened a new position in Neuropace (NPCE) in Q1 2026: 300 shares worth $3.94K. The stake represents ﹤0.01% of the portfolio and ranks #3874 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Steward Partners Investment Advisory held 300 shares of Neuropace worth $3.94K as of Q1 2026.
  • Neuropace was a new Steward Partners Investment Advisory position in Q1 2026.
  • Neuropace made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3874 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.